PI3K-AKT-mTOR
Selected indexed studies
- PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? (Front Oncol, 2022) [PMID:35402264]
- Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. (Int J Mol Sci, 2023) [PMID:36901954]
- Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. (Mol Biomed, 2022) [PMID:36539659]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. (2023) pubmed
- PI3K/Akt/mTOR signaling pathway in cancer stem cells. (2022) pubmed
- PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? (2022) pubmed
- Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. (2022) pubmed
- PI3K/AKT/mTOR Pathway in Angiogenesis. (2011) pubmed
- PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies-New Therapeutic Possibilities. (2023) pubmed
- Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. (2020) pubmed
- PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond. (2020) pubmed
- PI3K/AKT/mTOR signaling pathway modulation by circular RNAs in breast cancer progression. (2023) pubmed
- PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review). (2024) pubmed